The Global Antibody Drug Conjugates (ADC) report, published by Report Ocean, presents a comprehensive analysis of the product’s/service industry, examining both historical patterns and future prospects from 2023 to 2031. This report serves as a valuable reference for businesses seeking to formulate effective strategies for the coming years, offering insights into the performance of organizations and the overall market in the previous year.
ADC Market Set for Promising Growth Forecast to Reach USD 14.4 Billion by 2027
The global ADC market is growing at an impressive CAGR. The growing advancement in linker technologies, coupled with extensive research & development in the medical field, is driving the growth of the global ADC market
Download Free Sample of This Strategic Report: https://reportocean.com/industry-verticals/sample-request?report_id=MR444
A recent study by the strategic consulting and market research firm Report Ocean revealed that the Global ADC market was worth USD 4,053.7 million in 2021. The market is further anticipated to reach USD 14,484.2 million in 2027 with a significant CAGR of 25.2% during the forecast period, i.e., 2022-2027. The increasing incidence of cancer cases across the globe is propelling the growth of the global ADC (antibody-drug conjugate) market. For instance, according to the American Cancer Society, the estimated number of new cancer cases and deaths recorded for 2021 were around 1.9 million and 608,570, respectively, across the United States. In the coming years, ADC drug development will be facilitated by the increasing number of governmental healthcare programs and grants awarded to certain research organizations. Such factors, coupled with an increasing number of FDA approvals positively impact the growth of the global ADC Market.
Rising Number of Trials Pertaining to ADC Drugs Creating Lucrative Opportunities for Market Growth
The American Cancer Society estimates 36 ongoing trials with more than 20 ADCs combined with immuno-oncology (IO) therapies. With an estimated 100+ clinical trials going on around the world in 2019, there has been a growing inclination toward the production of ADCs in the market. Moreover, with the increasing number of approvals from the Food & Drug Administration (FDA), the ADC drug class has started to become an emerging drug in the market. However, some strict regulations have rendered over 20% of the ADC trials null and void. The FDA has found that more than 12 of the ADC drugs are in Phase II or Phase III (final stage) clinical trials, suggesting a growing number of approvals that the FDA may deliver in the coming years, thereby providing more opportunities for the growth of the market as these drugs could start to become accessible by low and middle-income countries that have long been eluded from the ADC drugs owing to their skyrocketing prices.
Downstream Processing & Technological Issues with ADC Anticipated to Impede Market Growth
Companies in the antibody-drug conjugate market report that the downstream processing process is a significant challenge impeding their growth. The production capabilities for suitable chemical linkers for connecting monoclonal antibodies and cytotoxic drugs are the biggest challenge across the downstream process for manufacturing and developing cost-effective ADC and are expected to impede the market growth.
Impact of COVID-19 on the Global ADC Market
The COVID-19 pandemic has had a mixed impact on the global ADC market. The ADC has proven beneficial in treating cancer. According to the American Cancer Society, an estimated 1.8 million newer cancer cases and almost 606,500 cancer deaths were recorded in 2020. The number of cases recorded in 2020 were higher than the number of cases in 2019, which were 1.7 million. Thus, the growing incidence of cancer led to the growing demand for ADC during the pandemic. However, due to the lockdown and supply chain disruptions, factory operations were reduced, which resulted in reduced clinical studies and unavailability of important raw materials, monoclonal antibodies (mAbs), linkers, and technology involved in the production of ADCs. All these factors have negatively impacted the growth of the global antibody-drug conjugate market.
Cleavable Type Segment Accounted for Major Highest Market Share in the Growth of Global ADC Market
Based on types, the global ADC market is segmented into cleavable linkers and non-cleavable linkers. The cleavable linkers segment accounted for the largest market share in 2021. The rise in approval rate and pipeline molecules, coupled with the ongoing trial of cleavable linkers, are the key factors driving the segments growth. For instance, in September 2021, Japan’s Ministry of Health, Labor, and Welfare (MHLW) announced that they were issuing a license for PADCEV (enfortumab vedotin), as it has been profoundly found to tackle unresectable urothelial carcinoma, which has augmented anti-cancer chemotherapy capabilities, according to the research conducted by Seagen Inc. and Astellas Pharma Inc. The ADC approved by the Ministry happens to be a cleavable linker ADC used for treating urothelial cancer.
Request To Download Sample of This Strategic Report:- https://reportocean.com/industry-verticals/sample-request?report_id=MR444
North America Dominates the Global ADC Market
Based on regions, the global ADC market is segmented into North America, Europe, the Asia-Pacific, Latin America, and the Middle East & Africa. The North America region held the largest market share in 2021. On the other hand, the Asia-Pacific region is expected to hold the largest CAGR during the forecast period. The increase in cancer cases in Asia-Pacific can be attributed to a variety of causes, including unhealthy lifestyles influenced by Western culture, the increase in alcohol and tobacco consumption, and the rise in pollution in South and Southeast Asia. Another factor contributing to the growth of cancer rates include the growing geriatric population.
Market Overview
Market Estimates & Forecast by Value, 2017-2027
By Value (USD Million)
Market Share & Forecast
By Type
Cleavable Linker
Non-cleavable Linker
By Application
Blood Cancer
Leukemia
Multiple Myeloma
Lymphoma
Breast Cancer
Urothelial Cancer & Bladder Cancer
Others
By End Users
Research Institutes
Biotechnology Companies
Hospitals
Clinics
By Region
North America
Europe
The Asia-Pacific (APAC)
Latin America (LATAM)
The Middle-East & Africa (MEA)
Global ADC Market – Competitive Landscape
The major companies in the global ADC market are F. Hoffmann-La Roche AG, Seagen, Inc. (Seattle Genetics Inc.), Daiichi Sankyo Company Ltd., AstraZeneca plc, Pfizer Inc., GlaxoSmithKline plc, Gilead Sciences, Inc., Takeda Pharmaceutical Company Limited, Genentech Inc., Astellas Pharma Inc., and other prominent players. The growing number of clinical trials for ADC products, including Trastuzumab Deruxtecan (DS-8201a), Sacituzumab govitecan, Mirvetuximab Soravtansine (IMGN853), Enfortumab Vedotin, Trastuzumab Duocarmazine (SYD985), and others, have demonstrated the growing competition in the market for breast as well as ovarian cancer, which is expected to enhance some competition in the market.
You Can Browse The Sample Report here:- https://reportocean.com/industry-verticals/sample-request?report_id=MR444
Some of the Key Questions Answered in this Report:
What are the key market trends and market dynamics?
Who are the major players in the market and what is their market share?
What is the competitive landscape like in the market?
What are the major drivers and restraints affecting the market?
What are the growth opportunities in the market?
What are the regional and local market conditions and consumer behavior?
What is the market size and growth forecast for different regions and countries?
What is the impact of government regulations and policies on the market?
Reasons to Buy:
Informed decision-making: Market research reports provide valuable insights into industry trends, customer behavior, and competitor analysis. This information can help businesses make informed decisions about product development, pricing, and marketing strategies.
Competitive advantage: By identifying market gaps and opportunities, market research reports can provide a competitive advantage that can help businesses differentiate themselves from their competitors and gain a larger share of the market.
Industry expertise: Market research reports are prepared by industry experts who have a deep understanding of the market and its dynamics. These reports provide an unbiased and objective view of the industry, which can be invaluable for businesses that want to gain a deeper understanding of the market.
Saves time and money: Conducting market research can be time-consuming and expensive. By purchasing a market research report, businesses can save time and money by accessing a comprehensive and detailed analysis of the market.
Risk management : Market research reports can help businesses manage risks associated with market entry, product development, and expansion. By providing a detailed analysis of the market and its trends, businesses can make informed decisions that minimize risks and maximize returns.
Request full Report– https://reportocean.com/industry-verticals/sample-request?report_id=MR444
About Report Ocean:
We are the best market research reports provider in the industry. Report Ocean believes in providing quality reports to clients to meet the top line and bottom line goals which will boost your market share in today’s competitive environment. Report Ocean is a ‘one-stop solution’ for individuals, organizations, and industries that are looking for innovative market research reports.
Get in Touch with Us:
Report Ocean:
Email:sales@reportocean.com
Address: 500 N Michigan Ave, Suite 600, Chicago, Illinois 60611 – UNITED STATES
Tel:+1 888 212 3539 (US – TOLL FREE)
Website:https://www.reportocean.com